

Supplementary tables

Table S1. Desmet verbal grading and staging of chronic hepatitis

Correlation between semiquantitative grading and verbal assessment of biopsies	
Minimal chronic hepatitis	1-3
Mild chronic hepatitis	4-8
Moderate chronic hepatitis	9-12
Severe chronic hepatitis	13-18
Scoring systems for staging of chronic hepatitis	
No fibrosis	0
Mild fibrosis	1
Moderate fibrosis	2
Severe fibrosis	3
Cirrhosis	4

Table S2. Baseline characteristics of the studied (AIH) children (N = 100)

Variables	Response to treatment			χ^2	P-value
	Complete response (n = 82)	Partial response (n = 11)	Non-responder (n = 7)		
Age at presentation (years)					
Range	1.50-17.00	1.00-16.00	2.00-16.00	H = 0.315	0.731
Median (IQR)	6.00 (5.00)	9.00 (7.00)	3.00 (10.00)		
Sex, n (%)					
Male	29 (35.4)	6 (54.5)	4 (57.1)	2.541	0.281
Female	53 (64.6)	5 (45.5)	3 (42.9)		
AIH type, n (%)					
Type 1 AIH	60 (73.17)	10 (90.91)	5 (71.43)	3.416	0.491
Type 2 AIH	9 (10.98)	0 (0.00)	0 (0.00)		
Seronegative AIH	13 (15.85)	1 (9.09)	2 (28.57)		
Treatment line, n (%)					
Corticosteroid alone	13 (15.9)	0 (0)	2 (28.6)	2.999	0.223
Corticosteroid + azathioprine	69 (84.1)	11 (100)	5 (71.4)		

AIH – autoimmune hepatitis, IH – immune hepatitis, χ^2 – chi square test, H – Kruskal-Wallis test; *significant

Table S3. Comparison of liver biopsy among treatment response groups of children with AIH ($N = 100$)

Variables	Response to treatment			χ^2	P-value
	Complete response ($n = 82$)	Partial response ($n = 11$)	Non-responder ($n = 7$)		
Fibrosis stage					
No	6 (7.3)	0 (0.0)	1 (14.3)	8.568	0.047*
Mild (1-2)	28 (34.1)	3 (27.3)	0 (0.0)		
Moderate (3-4)	34 (41.5)	8 (72.7)	4 (57.1)		
Severe (5-6)	14 (17.1)	0 (0.0)	2 (28.6)		
Activity grading					
Minimal (1-3)	1 (1.2)	0 (0.0)	1 (14.3)	8.709	0.042*
Mild (4-8)	49 (59.8)	6 (54.5)	2 (28.6)		
Moderate (9-13)	26 (31.7)	3 (27.3)	3 (42.9)		
Severe (14-18)	6 (7.3)	2 (18.2)	1 (14.3)		

AIH – autoimmune hepatitis, χ^2 – chi square test, H – Kruskal-Wallis test; *significant

Table S4. Autoantibodies among AIH treatment response groups ($N = 100$)

Variables	Response to treatment			χ^2	P-value
	Complete response ($n = 82$)	Partial response ($n = 11$)	Non-responder ($n = 7$)		
Anti-nuclear antibody (ANA)					
Negative	61 (74.39)	7 (63.64)	6 (85.71)	1.2	0.571
Positive	21 (25.61)	4 (36.36)	1 (14.29)		
Anti-smooth muscle antibody (ASMA)					
Negative	16 (19.51)	1 (9.09)	4 (57.14)	6.56	0.038*
Positive	66 (80.49)	10 (90.91)	3 (42.86)		
Anti liver kidney microsomal-1 antibody (LKM-1)					
Negative	73 (89.02)	11 (100.00)	7 (100.00)	2.17	0.338
Positive	9 (10.98)	0 (0.00)	0 (0.00)		

Table S5. Comparison of baseline characteristics among the AIH types of groups of studied children ($N = 100$)

Variables	AIH types			χ^2	P-value
	Type 1 AIH ($n = 75$)	Type 2 AIH ($n = 9$)	Seronegative AIH ($n = 16$)		
Age at presentation (years)					
Range	4.00-17.00	3.00-12.00	2.00-16.00	H = 1.898	0.156
Median (IQR)	9.00 (3.50)	6.00 (7.00)	3.00 (10.00)		
Sex, n (%)					
Male	29 (38.7)	1 (11.1)	9 (56.3)	4.947	0.084
Female	46 (61.3)	8 (88.9)	7 (43.8)		
Treatment, n (%)					
Corticosteroid alone	13 (17.3)	0 (0.0)	2 (12.5)	1.987	0.370
Corticosteroid + azathioprine	62 (82.7)	9 (100.0)	14 (87.5)		
Fibrosis stage, n (%)					
No	5 (6.7)	0 (0.0)	2 (12.5)	14.333	0.026*
Mild (1-2)	23 (30.7)	0 (0.0)	8 (50)		
Moderate (3-4)	38 (50.7)	6 (66.7)	2 (12.5)		
Severe (5-6)	9 (12.0)	3 (33.3)	4 (25)		
Activity grading, n (%)					
Minimal (1-3)	2 (2.7)	0 (0.0)	0 (0)	1.437	0.964
Mild (4-8)	42 (56.0)	6 (66.7)	9 (56.25)		
Moderate (9-13)	24 (32.0)	2 (22.2)	6 (37.5)		
Severe (14-18)	7 (9.3)	1 (11.1)	1 (6.25)		

AIH – autoimmune hepatitis, IH – immune hepatitis, χ^2 – chi square test, H – Kruskal-Wallis test; *significant